Physician profile
Andrew Poulos
NPI 1760801120
$2,380.34
in general payments reported to CMS, 2019-2025
24 companies · $886 in 2025
The $886 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.89 · 2022: $22.66 · 2023: $510 · 2024: $878 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $304.16 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Alkermes, INC. | $259.63 | 2023-2025 | Aristada, Lybalvi |
| Abbvie INC. | $258.67 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.09 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $193.74 | 2022-2025 | Abilify Maintena, Rexulti |
| Amgen INC. | $192.28 | 2019-2025 | Repatha, Evenity, Krystexxa |
| Neurocrine Biosciences, INC. | $149.26 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $131.32 | 2023-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $100.89 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $97.47 | 2023-2025 | Shingrix, Arexvy |
| Ironshore Pharmaceuticals INC. | $76.65 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $71.58 | 2025 | Spravato |
| Exact Sciences Corporation | $67.13 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $38.69 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $31.24 | 2025 | Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.31 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.93 | 2024 | Jardiance, Tradjenta |
| Calliditas Therapeutics US INC. | $25.93 | 2025 | Tarpeyo |
| Mylan Specialty L.P. | $23.56 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $22.53 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.05 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $15.45 | 2019 | |
| Lundbeck LLC | $14.82 | 2025 | Rexulti |
| Pfizer INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Poulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.